Superworth

Natera price to sales ratio NTRA

Market value divided by revenue over the last twelve months, since 2016.

Today, Nov 3, 2026
20.7×
10-year median
8.7×
Against its 10-year history
92nd
percentile: 0 is its lowest day, 100 its highest
10-year range
1.8× to 29.3×
Peer median
6.6×

Natera's price to sales ratio is 20.7× as of Nov 3, 2026.

That is above its ten-year median of 8.7×, higher than on 92% of days in the last ten years.

Over that time it ranged from 1.8× in Apr 2017 to 29.3× in Feb 2021.

The median for 10 diagnostics and research stocks of a similar size is 6.6×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far20.2×10.7×22.1×
202515.2×10.0×15.9×
202413.8×7.4×14.8×
20237.6×4.6×8.0×
20225.1×4.5×12.6×
202115.6×14.5×29.3×
202023.5×6.5×26.4×
20199.1×3.2×10.8×
20183.3×2.3×7.5×
20172.3×1.8×3.7×
20162.8×2.1×3.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Natera's size, closest first, today.

CompanyPrice to sales ratio
NTRANatera20.7×
IDXXIDEXX Laboratories11.4×
AAgilent Technologies6.7×
WATWaters10.0×
IQVIQVIA2.5×
ILMNIllumina8.0×
MTDMettler-Toledo International8.3×
LHLabcorp2.0×
DGXQuest Diagnostics2.3×
DHRDanaher6.3×
MEDPMedpace6.5×
Peer median6.6×

Where Natera ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Natera

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.